Evaluation of the Pharmacokinetics and Safety of a Single Dose of Acalabrutinib in Subjects With Hepatic Impairment

Acalabrutinib received approval for the treatment of adult patients with mantle cell lymphoma who received at least 1 prior therapy and adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. This study investigated the impact of hepatic impairment (HI) on acalabrutinib pharm...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yan, Izumi, Raquel, Nguyen, Helen, Kwan, Anna, Kuo, Howard, Madere, Jeannine, Slatter, J. Greg, Podoll, Terry, Vishwanathan, Karthick, Marbury, Thomas, Smith, William, Preston, Richard A., Sharma, Shringi, Ware, Joseph A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Special Populations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303693/
https://www.ncbi.nlm.nih.gov/pubmed/34897701
http://dx.doi.org/10.1002/jcph.2013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303693/
https://www.ncbi.nlm.nih.gov/pubmed/34897701
http://dx.doi.org/10.1002/jcph.2013

Ejemplares similares